CA
NZ
UK
AU
IND
US
For the nine months ended September 30, 2026, diluted EPS was $2.32, up 19.6% from $1.94. Return on averageAssetswas 1.38%, against 1.35% a year ago, while return on average shareholders'Equitywas 12.03% versus 11.92%.
Total revenues rose by $4.0 million to $402.7 million from $398.7 million. On a calculated basis, that is growth of about 1.0%, achieved despite a $23.1 million decline in revenues from non-comparable properties that were sold.
Compared with the second quarter, net income rose 32% from $22 million, while revenues slipped 6% from $497 million. AnnualizedReturn on Equitywas 3%, versus 2% in the prior quarter and 18% a year earlier.
Net investment income fell to $36 million from $73 million in the prior quarter and $99 million a year earlier. Adjusted net income, a non-GAAP measure, was $30 million, or $0.35 per share, which the company said equals an annualized adjustedReturn on Equityof 9%. …
Revenue was $410.1 million, up $55.5 million from $354.7 million a year earlier. Thrombectomy revenue rose 18.1% to $279.2 million, which the company attributed mainly to higher U.S.Volumefrom new products and further penetration of existing ones. Embolization and access revenue rose 10.8% to $131.0 …
The number of ads served rose 17%, while the price of ads fell 4%. Global average revenue per user was $1.80, up 1%, and average monthly active users grew 10%, so most of the growth came from a larger audience rather than higher monetization …
Bookings were a record, expected to generate $855 million of annualized GAAP base rent at 100% share, or $627 million at the company's share. Backlog of signed but not commenced leases was a record $2.5 billion at 100% share and $1.8 billion at the …
Consulting & Engineering Services brought in $1,213 million, down 3.3% organically, with a segmentMarginof 10.3%. Global Infrastructure Services revenue was $1,427 million, down 10.0%, and its segment profit dropped 45.9% to $66 million, a margin of 4.6%.
Higher prices were primarily driven by higher raw material and distribution costs and tight market conditions in Chemical Intermediates because of the ongoing conflict in the Middle East. CEO Mark Costa said the company implemented higher sequential price increases in its specialties and remains …
Net income available to common shareholders was $724 million, down $108 million from $832 million. BasicEarnings Per Sharewere $1.88 versus $2.16, andDiluted Earnings per Sharewere $1.87 versus $2.16.
Please wait processing your request...